To compare quantitatively the efficacy and tolerability of pharmacologically active interventions in the treatment and prevention of alcohol-induced hangover. MethodsSystematic review of placebo-controlled randomised trials in healthy adults that evaluated any pharmacologically active intervention in the treatment or prevention of hangover. We searched Medline, Embase, PsycINFO and CENTRAL from database inception until 1st August 2021.… Continue reading The efficacy and tolerability of pharmacologically active interventions for alcohol-induced hangover symptomatology: A systematic review of the evidence from randomised placebo-controlled trials
Category: Hepatology
Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)
Hypoglycemia induced by direct-acting antiviral agents (DAAs) for chronic hepatitis C virus (HCV) infection is a rare but potentially life-threatening adverse reaction, which led to warnings by competent authorities. We therefore aimed to examine the hypoglycemic safety signal for DAAs. MethodsReports to the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 1… Continue reading Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)
Food Insecurity is Associated with Mortality Among U.S. Adults with Nonalcoholic Fatty Liver Disease and Advanced Fibrosis
Food insecurity is a growing public health challenge in the U.S. and has been linked to nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis. However, little is known of how food insecurity impacts mortality risk and healthcare utilization (HCU) in chronic liver disease. MethodsUsing a population-based cohort study of U.S. adults (≥20 years) in the… Continue reading Food Insecurity is Associated with Mortality Among U.S. Adults with Nonalcoholic Fatty Liver Disease and Advanced Fibrosis
Liver expression of IL-22, IL-22R1 and IL-22BP in patients with chronic hepatitis C with different fibrosis stages
Highlights•Liver biopsies at stage F1 to F3 expressed more IL-22 than F0 or F4. •The number of cells expressing IL-22R1 decreased as fibrosis increased. •There was an increase in Il-22BP staining in more advanced stages of fibrosis. •IL-22 pathway may be involved in the pathophysiology of liver fibrosis. AbstractLiver fibrosis is the result of an… Continue reading Liver expression of IL-22, IL-22R1 and IL-22BP in patients with chronic hepatitis C with different fibrosis stages
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
Patients with NASH, NAS≥4, and F≥2 (Fibro-NASH) are at highest risk for disease progression.➢Patients with Fibro-NASH are targeted for proof-of-concept NASH trials.➢MRI-PDFF and MR elastography are the most common primary and secondary endpoints in NASH trials, respectively.➢To identify Fibro-NASH, the MRI-AST (MAST) score was created based on these MRI techniques.➢The MAST score was proven to… Continue reading MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study
•EDP-305 is an oral farnesoid X receptor (FXR) agonist being developed to treat nonalcoholic steatohepatitis (NASH).•In a randomized, placebo-controlled study, 12-week study, EDP-305 reduced ALT levels and MRI-PDFF•These results support further development of EDP-305 in patients with NASH with longer term studies. ABSTRACTBackground & AimsEDP-305 is an oral farnesoid X receptor (FXR) agonist under development… Continue reading EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study
Hepatitis #C Virus Reactivation Following #COVID-19 Vaccination – A Case Report
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection impacted morbidity and mortality during the pandemic of 2020–2021. A number of anti-COVID-19 vaccines have been developed with an unprecedented speed. While these vaccines have good efficacy and are safe, the experience with their use is limited and hence the knowledge of rare side effects. Identifying rare… Continue reading Hepatitis #C Virus Reactivation Following #COVID-19 Vaccination – A Case Report
ADAMTSL2 protein and a soluble biomarker signature identify significant and advanced #fibrosis in adults with #NAFLD
Using an aptamer-based profiling platform we identified an individual and panel of circulating proteins that non-invasively identify significant fibrosis at-risk NASH in 316 adults with NAFLD.•An 8-protein panel can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage 2-4 with an AUROC 0.87- 0.89.•The ADAMTSL2 protein alone can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage… Continue reading ADAMTSL2 protein and a soluble biomarker signature identify significant and advanced #fibrosis in adults with #NAFLD
Metabolic associated fatty #liver disease is the risk factor for chronic #kidney disease
Background & AimsTo clarify the relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and chronic kidney disease (CKD). MethodsThe participants were divided into four groups by the presence or absence of fatty liver disease (FLD) and metabolic dysfunction (MD). MAFLD was defined as having both FLD and MD, whereas CKD was defined as estimated glomerular… Continue reading Metabolic associated fatty #liver disease is the risk factor for chronic #kidney disease
